Getting Started

How Wegovy Works

Whether you are weighing up Wegovy for the first time or trying to understand exactly how it acts in the body, this guide walks through how Wegovy works for weight loss, what the clinical trials show, and what UK patients can expect when starting treatment. LetsLoseWeight is an independent comparison site; we are not affiliated with any pharmacy or provider, and we do not sell or prescribe medication.

What is Wegovy?

Wegovy is the brand name used by Novo Nordisk for semaglutide 2.4mg, a once-weekly prescription injection licensed by the MHRA for weight management in adults. The same active ingredient — semaglutide — is also sold under the brand names Ozempic (for type 2 diabetes) and Rybelsus (an oral tablet for type 2 diabetes), but only Wegovy is licensed in the UK for weight management.

Wegovy is given as a small subcutaneous injection — usually in the abdomen, thigh or upper arm — and the dose is built up gradually over a 16-week schedule to reduce the risk of gastrointestinal side effects (Wegovy SmPC, EMC).

In March 2023, NICE Technology Appraisal TA875 recommended Wegovy for use within specialist NHS weight management services, with NHS access typically capped at two years. Outside the NHS, Wegovy is widely available through regulated UK online pharmacies — see our Wegovy UK guide for how access works in practice.

How Wegovy works in the body

Wegovy is a GLP-1 receptor agonist — meaning it mimics a natural gut hormone called glucagon-like peptide-1 (GLP-1), which the body releases from the small intestine after eating. GLP-1 is part of the body's normal appetite and blood sugar control system, but it breaks down within minutes of being released. Semaglutide is a long-acting version that keeps the GLP-1 signal active for the full week between injections.

There are four main effects.

1. It reduces appetite

Semaglutide acts on appetite centres in the brain — particularly the hypothalamus — to reduce hunger between meals and the urge to eat for reasons other than hunger. Many people describe feeling less preoccupied with food, with constant snacking thoughts becoming quieter.

2. It increases fullness after eating

By slowing the rate at which the stomach empties, Wegovy makes meals feel more filling and the feeling of fullness lasts longer. Smaller portions become more satisfying, which naturally reduces calorie intake.

3. It improves blood sugar control

Semaglutide stimulates the pancreas to release insulin when blood sugar is elevated, and reduces the release of glucagon (a hormone that raises blood sugar). Because the effect is glucose-dependent, the risk of low blood sugar (hypoglycaemia) is low when Wegovy is used on its own — though that risk can rise when combined with sulfonylureas or insulin in people who also have diabetes.

4. It supports steady weight loss alongside lifestyle change

The main clinical-trial evidence for Wegovy in weight management comes from the STEP 1 trial, published in the New England Journal of Medicine in 2021. In adults with overweight or obesity but without type 2 diabetes, average weight loss after 68 weeks was around 14.9% on semaglutide 2.4mg compared with around 2.4% on placebo. All participants also followed lifestyle interventions including a reduced-calorie diet and increased physical activity. (Wilding et al., NEJM 2021)

These figures are averages from trial conditions. Real-world results vary, and Wegovy is licensed as an adjunct to lifestyle change, not a replacement for it.

Why Wegovy is different from older weight-loss treatments

Before semaglutide, the main pharmacological options for weight management in the UK were orlistat (which reduces fat absorption in the gut) and, briefly, liraglutide (a daily GLP-1 injection sold as Saxenda, with smaller average weight loss than Wegovy in head-to-head trials). Wegovy was the first once-weekly GLP-1 to demonstrate sustained double-digit average weight loss, which is why it was described in the medical literature as a step-change in obesity pharmacotherapy.

It is now no longer the most potent option on average — head-to-head trials suggest tirzepatide (Mounjaro) achieves greater average weight loss than semaglutide (Aronne et al., SURMOUNT-5, NEJM 2025). But individual response varies, and Wegovy remains a strong, well-evidenced option, particularly for patients who tolerate it well or for whom Mounjaro is unsuitable. See our Mounjaro vs Wegovy UK comparison for a side-by-side breakdown.

What Wegovy is not

Wegovy is not a standalone weight-loss solution. The clinical trials, NICE guidance, and the MHRA licence all describe it as treatment to be used alongside a reduced-calorie diet and increased physical activity. The STEP 1 trial extension followed participants for a year after stopping semaglutide and found that, on average, two-thirds of the lost weight was regained within 12 months of stopping the drug (Wilding et al., 2022).

It is also a prescription-only medicine. In the UK it can only be supplied by a registered pharmacy after a clinical assessment by a qualified prescriber. Buying semaglutide without a prescription — from social-media sellers, "weight-loss clinics" overseas, or unregulated international websites — risks counterfeit product, incorrect dosing, and no clinical safety net.

Side effects to be aware of

The most commonly reported side effects of semaglutide are gastrointestinal: nausea, diarrhoea, constipation, vomiting and reduced appetite. They are usually most noticeable in the first weeks after starting or after a dose increase, and tend to settle as the body adjusts. Less common but more serious risks — including pancreatitis and gallbladder disease — are listed in the Wegovy Summary of Product Characteristics on the EMC.

For a fuller list and tips on managing side effects, see our Wegovy side effects guide.

Who Wegovy is for

The licensed indication and the NHS eligibility criteria are different. The full eligibility picture is covered in our who can take weight loss injections guide, but in summary:

  • Privately, the licensed indication covers adults with a BMI of 30 or above (obesity), or a BMI of 27 or above plus a weight-related health condition.
  • On the NHS, NICE TA875 sets a higher threshold and adds further conditions: a BMI of at least 35 with at least one weight-related comorbidity (or 30–34.9 with referral criteria met), within a specialist multidisciplinary weight management service, and capped at two years of treatment. The BMI threshold is reduced by 2.5 for people from South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean ethnic backgrounds.

Frequently asked questions

How quickly does Wegovy start working?
Most people notice reduced appetite within the first one to two weeks. Visible weight changes typically follow over the first two to four months as the dose is gradually titrated upwards. The full clinical effect is usually assessed at the maintenance dose of 2.4mg, reached around week 17.

How long is Wegovy taken for?
Privately, treatment can continue long-term as long as it remains clinically appropriate and is being reviewed. On the NHS, NICE TA875 caps treatment at two years.

What happens if I stop Wegovy?
Weight regain is common after stopping, especially without continued lifestyle support. The STEP 1 trial extension found that participants regained around two-thirds of their lost weight within a year of stopping the drug.

Is Wegovy the same as Ozempic?
The active ingredient is the same (semaglutide), but the products are not interchangeable. Wegovy is licensed for weight management at doses up to 2.4mg weekly. Ozempic is licensed only for type 2 diabetes at lower maximum doses. UK regulators and NHS England have specifically warned against using Ozempic off-label for weight loss because it diverts supply from people with diabetes.

Is Wegovy the same as semaglutide tablets (Rybelsus)?
No. Rybelsus is an oral tablet form of semaglutide licensed only for type 2 diabetes in the UK, not for weight management.

Next steps

Sources

This guide is for general information only and is not a substitute for professional medical advice. Talk to a qualified prescriber about whether Wegovy is suitable for you.

Get weekly weight loss tips

Join our newsletter for provider updates, expert guidance, and exclusive offers — no spam.

Subscribe free
Back to Guides
How Wegovy Works: GLP-1 Mechanism Explained UK | LetsLoseWeight